G. Finucane

Past Investigations May Be Misleading

G. Finucane, 2016 .

Varenicline improves motor and cognitive symptoms in early Huntington’s disease

R. Kydd, B. Russell, M. Tingle, 2016, Neuropsychiatric disease and treatment.

Use of antipsychotic medications in patients with Parkinson's disease at Auckland City Hospital

R. Roxburgh, B. Snow, G. Finucane, 2012, Internal medicine journal.

Temporal lobe resection for refractory temporal lobe epilepsy at Auckland Hospital.

R. Suppiah, P. Bergin, E. Mee, 2009, The New Zealand medical journal.

The Appointment of a Huntington's Disease Nurse Specialist has Reduced Admission Rate and Improved Admission Quality.

R. Roxburgh, D. Bourke, G. Finucane, 2012, Journal of Huntington's disease.

A phase IIb, randomised, double-blind, placebo-controlled, dose-ranging investigation of the safety and efficacy of NTCELL® [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease.

B. Snow, C. Frampton, E. Mulroy, 2019, Parkinsonism & related disorders.

A long-term follow-up of safety and clinical efficacy of NTCELL® [Immunoprotected (Alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease.

B. Snow, C. Frampton, E. Mulroy, 2020, Parkinsonism & related disorders.